

HLA-DR Conjugated Antibody

Catalog No: #C48982



Package Size: #C48982-AF350 100ul #C48982-AF405 100ul #C48982-AF488 100ul
#C48982-AF555 100ul #C48982-AF594 100ul #C48982-AF647 100ul
#C48982-AF680 100ul #C48982-AF750 100ul #C48982-Biotin 100ul

Orders: order@signalwayantibody.com
Support: tech@signalwayantibody.com

Description

Product Name	HLA-DR Conjugated Antibody
Host Species	Rabbit
Clonality	Monoclonal
Clone No.	SR4525
Species Reactivity	Human;Mouse
Immunogen Description	recombinant protein
Conjugates	Biotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750
Other Names	DR alpha chain antibody DR alpha chain precursor antibody DRA_HUMAN antibody DRB1 antibody DRB4 antibody Histocompatibility antigen HLA DR alpha antibody HLA class II histocompatibility antigen antibody HLA class II histocompatibility antigen DR alpha chain antibody HLA DR1B antibody HLA DR3B antibody HLA DRA antibody HLA DRA1 antibody HLA DRB1 antibody HLA DRB3 antibody HLA DRB4 antibody HLA DRB5 antibody HLA-DRA antibody HLADR4B antibody HLADRA1 antibody HLADRB antibody Major histocompatibility complex class II DR alpha antibody Major histocompatibility complex class II DR beta 1 antibody Major histocompatibility complex class II DR beta 3 antibody Major histocompatibility complex class II DR beta 4 antibody Major histocompatibility complex class II DR beta 5 antibody MGC117330 antibody MHC cell surface glycoprotein antibody MHC class II antigen DRA antibody MHC II antibody MLRW antibody
Accession No.	Swiss-Prot#:P01903
Uniprot	P01903
GeneID	3122;
Excitation Emission	AF350: 346nm/442nm AF405: 401nm/421nm AF488: 493nm/519nm AF555: 555nm/565nm AF594: 591nm/614nm AF647: 651nm/667nm AF680: 679nm/702nm AF750: 749nm/775nm
Calculated MW	29 kDa
Formulation	0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
Storage	Store at 4°C in dark for 6 months

Application Details

Suggested Dilution:
AF350 conjugated: most applications: 1: 50 - 1: 250

AF405 conjugated: most applications: 1: 50 - 1: 250

AF488 conjugated: most applications: 1: 50 - 1: 250

AF555 conjugated: most applications: 1: 50 - 1: 250

AF594 conjugated: most applications: 1: 50 - 1: 250

AF647 conjugated: most applications: 1: 50 - 1: 250

AF680 conjugated: most applications: 1: 50 - 1: 250

AF750 conjugated: most applications: 1: 50 - 1: 250

Biotin conjugated: working with enzyme-conjugated streptavidin, most applications: 1: 50 - 1: 1,000

Background

Major histocompatibility complex (MHC) class II molecules destined for presentation to CD4+ helper T cells is determined by two key events. These events include the dissociation of class II-associated invariant chain peptides (CLIP) from an antigen binding groove in MHC II α/β dimers through the activity of MHC molecules HLA-DM and -DO, and subsequent peptide antigen binding. Accumulating in endosomal/lysosomal compartments and on the surface of B cells, HLA-DM, -DO molecules regulate the dissociation of CLIP and the subsequent binding of exogenous peptides to HLA class II molecules (HLA-DR, -DQ and -DP) by sustaining a conformation that favors peptide exchange. RFLP analysis of HLA-DM genes from rheumatoid arthritis (RA) patients suggests that certain polymorphisms are genetic factors for RA susceptibility. HLA-B belongs to the HLA class I heavy chain paralogs. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. HLA-B and -C can form heterodimers consisting of a membrane anchored heavy chain and a light chain (β -2-Microglobulin). Polymorphisms yield hundreds of HLA-B and -C alleles.

Note: This product is for in vitro research use only